secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2023-04-26T23:59:59+00:00
Accession:  0001193125-23-116976
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks to transfer zanidatamab program to Jazz; Jazz acquires ZZI subsidiary
-------------------------------------------------------------------------------

- On April 25, 2023, Zymeworks entered a Stock and Asset Purchase Agreement with Jazz Pharmaceuticals to transfer the zanidatamab program.
- Jazz will acquire 100% of ZZI, a Zymeworks subsidiary focused on zanidatamab, and related assets and employees.
- No Zymeworks common stock is sold; Jazz assumes responsibility for development and commercialization under an amended collaboration agreement.
- Zymeworks retains rights to ZW49 (zanidatamab zovodotin) and will continue to supply zanidatamab to clinical sites.
- Closing expected in May 2023; financial terms of the original collaboration agreement remain unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312523116976/0001193125-23-116976-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312523116976/d292152d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-116976

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer